Soc. Generale Bonus Zert AMD 27.0.../ DE000SU9Y6G1 /
15/05/2024 08:30:05 | Chg.+2.15 | Bid16:55:28 | Ask16:55:28 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
148.65EUR | +1.47% | 151.48 Bid Size: 5,000 |
151.64 Ask Size: 5,000 |
Advanced Micro Devic... | - USD | 27/06/2025 | Call |
GlobeNewswire
14/05
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
14/05
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire
14/05
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
13/05
AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire
09/05
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire
08/05
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire
08/05
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
08/05
AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire
08/05
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire
08/05
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire
07/05
Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire
07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
06/05
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire
06/05
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire
06/05
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...